Generics· May 6, 2026 · 3 min read
Generic entry, ANDA, and 505(b)(2): the commercial difference
ANDA and 505(b)(2) pathways answer different commercial problems. Launch teams should separate therapeutic equivalence, reliance strategy, exclusivity, and payer...
By Ran Chen#Generics#505(b)(2)#Orange Book